Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Screening of specific antigens for SARS clinical diagnosis using a protein microarray

Identifieur interne : 004965 ( Main/Exploration ); précédent : 004964; suivant : 004966

Screening of specific antigens for SARS clinical diagnosis using a protein microarray

Auteurs : Dan-Dan Lu [République populaire de Chine] ; Su-Hong Chen [République populaire de Chine] ; Shi-Meng Zhang [République populaire de Chine] ; Min-Li Zhang [République populaire de Chine] ; Wei Zhang [République populaire de Chine] ; Xiao-Chen Bo [République populaire de Chine] ; Sheng-Qi Wang [République populaire de Chine]

Source :

RBID : ISTEX:ED6A1E05919B52ABD2FC81D99BBBC2623094027C

Descripteurs français

English descriptors

Abstract

In this study several SARS-CoV structural proteins and fragments were expressed in E. coli as GST or TRX fusion proteins. They were fabricated on a microarray and tested with sera from SARS patients. Antigenic screening indicated that recombinant GST-N2 fusion protein, the carboxy-terminus 213aa–423aa of N protein, was strongest positive and weakest non-specific compared with others. An indirect antibody ELISA method was developed and clinical positive and negative sera for their antibodies against GST-N2 fusion protein were assayed. 311 out of the 442 sera from clinical SARS inpatients, as well as 229 out of 302 sera from convalescent patients gave positive reactivities; positive rates were 70.4% and 75.8% respectively. Sera from a total of 2726 non-SARS patients and healthy individuals were tested and the false positive rate was only 0.07%. When the sensitivity control sample was diluted 1 ∶ 64, it yielded OD values above the cutoff value. Reported data showed that this was a relatively high degree of sensitivity and specificity for SARS-CoV antibody testing. The data indicate that GST-N2 fusion protein, which was screened by protein microarray, may be a valuable diagnostic antigen for the development of serological assays for SARS. In addition, protein microarray assay presents a higher positive rate and sensitivity (86.1% and 1 ∶ 200) compared with the traditional ELISA screening method, and could provide a rapid, parallel and high-throughput antigen screening platform.

Url:
DOI: 10.1039/b415888a


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Screening of specific antigens for SARS clinical diagnosis using a protein microarray</title>
<author wicri:is="90%">
<name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
</author>
<author wicri:is="90%">
<name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
</author>
<author wicri:is="90%">
<name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
</author>
<author wicri:is="90%">
<name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
</author>
<author wicri:is="90%">
<name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
</author>
<author wicri:is="90%">
<name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
</author>
<author wicri:is="90%">
<name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ED6A1E05919B52ABD2FC81D99BBBC2623094027C</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1039/b415888a</idno>
<idno type="url">https://api.istex.fr/ark:/67375/QHD-7B8CRX67-C/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000001</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000001</idno>
<idno type="wicri:Area/Istex/Curation">000001</idno>
<idno type="wicri:Area/Istex/Checkpoint">001826</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001826</idno>
<idno type="wicri:doubleKey">0003-2654:2005:Lu D:screening:of:specific</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15776156</idno>
<idno type="wicri:Area/PubMed/Corpus">002837</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002837</idno>
<idno type="wicri:Area/PubMed/Curation">002837</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002837</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002503</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002503</idno>
<idno type="wicri:Area/Ncbi/Merge">000E44</idno>
<idno type="wicri:Area/Ncbi/Curation">000E44</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E44</idno>
<idno type="wicri:doubleKey">0003-2654:2005:Lu D:screening:of:specific</idno>
<idno type="wicri:Area/Main/Merge">004C93</idno>
<idno type="wicri:Area/Main/Curation">004965</idno>
<idno type="wicri:Area/Main/Exploration">004965</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Screening of specific antigens for SARS clinical diagnosis using a protein microarray</title>
<author wicri:is="90%">
<name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%">
<name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%">
<name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%">
<name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%">
<name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%">
<name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
<author wicri:is="90%">
<name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
<affiliation wicri:level="3">
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Institute of Radiation Medicine, 100850, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">République populaire de Chine</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Analyst</title>
<title level="j" type="abbrev">Analyst</title>
<idno type="ISSN">0003-2654</idno>
<idno type="eISSN">1364-5528</idno>
<imprint>
<publisher>The Royal Society of Chemistry.</publisher>
<date type="published" when="2005">2005</date>
<biblScope unit="volume">130</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="474">474</biblScope>
<biblScope unit="page" to="482">482</biblScope>
</imprint>
<idno type="ISSN">0003-2654</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0003-2654</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antibodies, Viral (analysis)</term>
<term>Antigens, Viral (isolation & purification)</term>
<term>Bioreactors</term>
<term>Case-Control Studies</term>
<term>Electrophoresis, Polyacrylamide Gel</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Escherichia coli</term>
<term>Humans</term>
<term>Immunoglobulin G (analysis)</term>
<term>Intracellular Signaling Peptides and Proteins (genetics)</term>
<term>Membrane Proteins</term>
<term>Organic Anion Transporters (genetics)</term>
<term>Protein Array Analysis</term>
<term>Recombinant Fusion Proteins (analysis)</term>
<term>SARS Virus (immunology)</term>
<term>Sensitivity and Specificity</term>
<term>Severe Acute Respiratory Syndrome (diagnosis)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Analyse par réseau de protéines</term>
<term>Anticorps antiviraux (analyse)</term>
<term>Antigènes viraux (isolement et purification)</term>
<term>Bioréacteurs</term>
<term>Escherichia coli</term>
<term>Humains</term>
<term>Immunoglobuline G (analyse)</term>
<term>Protéines de fusion recombinantes (analyse)</term>
<term>Protéines et peptides de signalisation intracellulaire (génétique)</term>
<term>Protéines membranaires</term>
<term>Sensibilité et spécificité</term>
<term>Spectrométrie de masse MALDI</term>
<term>Syndrome respiratoire aigu sévère (diagnostic)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Test ELISA ()</term>
<term>Transporteurs d'anions organiques (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Électrophorèse sur gel de polyacrylamide</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Intracellular Signaling Peptides and Proteins</term>
<term>Organic Anion Transporters</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en">
<term>Antigens, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr">
<term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
<term>Protéines de fusion recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Protéines et peptides de signalisation intracellulaire</term>
<term>Transporteurs d'anions organiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Antigènes viraux</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Enzyme-Linked Immunosorbent Assay</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Affinity column</term>
<term>Amersham pharmacia</term>
<term>Amino acids</term>
<term>Antibody screening</term>
<term>Antibody testing</term>
<term>Antigen screening platform</term>
<term>Antigenic</term>
<term>Antisense primers</term>
<term>Assay</term>
<term>Beijing</term>
<term>Beijing hospital</term>
<term>Bioreactors</term>
<term>Calibration curve</term>
<term>Calibration curves</term>
<term>Case-Control Studies</term>
<term>Cell lysates</term>
<term>Clinical assessment</term>
<term>Clinical diagnosis</term>
<term>Clinical patient sera</term>
<term>Clinical trials</term>
<term>Coli</term>
<term>Coli dh5a</term>
<term>Convalescent patients</term>
<term>Coronavirus</term>
<term>Cutoff value</term>
<term>Detection limits</term>
<term>Detection wavelength</term>
<term>Different reactivities</term>
<term>Electrophoresis, Polyacrylamide Gel</term>
<term>Elisa</term>
<term>Elisa assay</term>
<term>Epidemiologic investigations</term>
<term>Escherichia coli</term>
<term>Experimental conditions</term>
<term>Expression plasmids</term>
<term>Fluorescence intensity</term>
<term>Fragment</term>
<term>Fusion protein</term>
<term>Fusion proteins</term>
<term>Gaattc</term>
<term>Gene fragments</term>
<term>Gene nucleotide sequence</term>
<term>Gene sequence</term>
<term>Ggatcc</term>
<term>Glass slides</term>
<term>Healthy individuals</term>
<term>High degree</term>
<term>Host cells</term>
<term>Human sera</term>
<term>Humans</term>
<term>Inpatient</term>
<term>Internal calibration curves</term>
<term>Lysates</term>
<term>Membrane Proteins</term>
<term>Microarray</term>
<term>Microarray assay</term>
<term>Microarrays</term>
<term>Molecular protein standards</term>
<term>Molecular weight</term>
<term>Negative control</term>
<term>Negative control sera</term>
<term>Negative sera</term>
<term>Novel coronavirus</term>
<term>Nucleocapsid proteins</term>
<term>Nucleotide</term>
<term>Nucleotide sequences</term>
<term>Oligonucleotide primers</term>
<term>Plasmid</term>
<term>Positive rates</term>
<term>Positive reactivity</term>
<term>Positive sera</term>
<term>Primer</term>
<term>Probable sars patients</term>
<term>Protein</term>
<term>Protein Array Analysis</term>
<term>Protein fragment screening microarray</term>
<term>Protein fragment screening microarrays</term>
<term>Protein fragments</term>
<term>Protein microarray</term>
<term>Protein microarray assay</term>
<term>Protein microarrays</term>
<term>Protein microarrays protein microarrays</term>
<term>Recombinant</term>
<term>Recombinant fusion protein</term>
<term>Recombinant proteins</term>
<term>Respiratory syndrome</term>
<term>Restriction sites</term>
<term>Royal society</term>
<term>Sars</term>
<term>Sars diagnosis</term>
<term>Sars disease</term>
<term>Sars infection</term>
<term>Sars inpatients</term>
<term>Sars outbreak</term>
<term>Sars patients</term>
<term>Sars sera</term>
<term>Scan images</term>
<term>Schematic representation</term>
<term>Screening</term>
<term>Screening microarrays</term>
<term>Sensitivity and Specificity</term>
<term>Sensitivity control sample</term>
<term>Serum samples</term>
<term>Sonication buffer</term>
<term>Specific antibodies</term>
<term>Specific antigens</term>
<term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term>
<term>Structural proteins</term>
<term>Structure protein screening microarrays</term>
<term>Traditional chinese</term>
<term>Various structure proteins</term>
<term>Vector protein</term>
<term>Western medicine</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Analyse par réseau de protéines</term>
<term>Bioréacteurs</term>
<term>Escherichia coli</term>
<term>Humains</term>
<term>Protéines membranaires</term>
<term>Sensibilité et spécificité</term>
<term>Spectrométrie de masse MALDI</term>
<term>Test ELISA</term>
<term>Électrophorèse sur gel de polyacrylamide</term>
<term>Études cas-témoins</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">In this study several SARS-CoV structural proteins and fragments were expressed in E. coli as GST or TRX fusion proteins. They were fabricated on a microarray and tested with sera from SARS patients. Antigenic screening indicated that recombinant GST-N2 fusion protein, the carboxy-terminus 213aa–423aa of N protein, was strongest positive and weakest non-specific compared with others. An indirect antibody ELISA method was developed and clinical positive and negative sera for their antibodies against GST-N2 fusion protein were assayed. 311 out of the 442 sera from clinical SARS inpatients, as well as 229 out of 302 sera from convalescent patients gave positive reactivities; positive rates were 70.4% and 75.8% respectively. Sera from a total of 2726 non-SARS patients and healthy individuals were tested and the false positive rate was only 0.07%. When the sensitivity control sample was diluted 1 ∶ 64, it yielded OD values above the cutoff value. Reported data showed that this was a relatively high degree of sensitivity and specificity for SARS-CoV antibody testing. The data indicate that GST-N2 fusion protein, which was screened by protein microarray, may be a valuable diagnostic antigen for the development of serological assays for SARS. In addition, protein microarray assay presents a higher positive rate and sensitivity (86.1% and 1 ∶ 200) compared with the traditional ELISA screening method, and could provide a rapid, parallel and high-throughput antigen screening platform.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
</country>
<settlement>
<li>Pékin</li>
</settlement>
</list>
<tree>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
</noRegion>
<name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
<name sortKey="Bo, Xiao Chen" sort="Bo, Xiao Chen" uniqKey="Bo X" first="Xiao-Chen" last="Bo">Xiao-Chen Bo</name>
<name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
<name sortKey="Chen, Su Hong" sort="Chen, Su Hong" uniqKey="Chen S" first="Su-Hong" last="Chen">Su-Hong Chen</name>
<name sortKey="Lu, Dan Dan" sort="Lu, Dan Dan" uniqKey="Lu D" first="Dan-Dan" last="Lu">Dan-Dan Lu</name>
<name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
<name sortKey="Wang, Sheng Qi" sort="Wang, Sheng Qi" uniqKey="Wang S" first="Sheng-Qi" last="Wang">Sheng-Qi Wang</name>
<name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
<name sortKey="Zhang, Min Li" sort="Zhang, Min Li" uniqKey="Zhang M" first="Min-Li" last="Zhang">Min-Li Zhang</name>
<name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
<name sortKey="Zhang, Shi Meng" sort="Zhang, Shi Meng" uniqKey="Zhang S" first="Shi-Meng" last="Zhang">Shi-Meng Zhang</name>
<name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
<name sortKey="Zhang, Wei" sort="Zhang, Wei" uniqKey="Zhang W" first="Wei" last="Zhang">Wei Zhang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004965 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004965 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:ED6A1E05919B52ABD2FC81D99BBBC2623094027C
   |texte=   Screening of specific antigens for SARS clinical diagnosis using a protein microarray
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021